Vogl, U. M., Andalibi, H., Klaus, A., Vormittag, L., Schima, W., Heinrich, B., . . . Öhler, L. (2019). Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: Does sequence matter? BMC Cancer.
Citação norma ChicagoVogl, Ursula M., Haleh Andalibi, Alexander Klaus, Laurenz Vormittag, Wolfgang Schima, Bettina Heinrich, Alice Kafka, Thomas Winkler, and Leopold Öhler. "Nab-paclitaxel and Gemcitabine or FOLFIRINOX As First-line Treatment in Patients With Unresectable Adenocarcinoma of the Pancreas: Does Sequence Matter?" BMC Cancer 2019.
Citação norma MLAVogl, Ursula M., et al. "Nab-paclitaxel and Gemcitabine or FOLFIRINOX As First-line Treatment in Patients With Unresectable Adenocarcinoma of the Pancreas: Does Sequence Matter?" BMC Cancer 2019.